Integrity Alliance LLC. Invests $706,000 in Sanofi $SNY

Key Points

• Integrity Alliance LLC has invested approximately $706,000 in Sanofi, acquiring 12,733 shares in the company during the first quarter.
• Despite a recent earnings miss of $0.90 EPS against an estimate of $0.96, Sanofi reported robust revenue of $11.34 billion for the quarter.
• Wall Street analysts show optimism on Sanofi, with many adjusting their ratings to buy and an average target price of $62.67.

Integrity Alliance LLC. acquired a new position in Sanofi (NASDAQ:SNY - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,733 shares of the company's stock, valued at approximately $706,000.

Several other hedge funds have also modified their holdings of the stock. Price T Rowe Associates Inc. MD lifted its position in Sanofi by 1.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,036,878 shares of the company's stock worth $612,106,000 after acquiring an additional 193,196 shares in the last quarter. Federated Hermes Inc. lifted its position in Sanofi by 58.5% during the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock worth $218,933,000 after acquiring an additional 1,456,269 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in Sanofi by 1.0% during the 4th quarter. Nuveen Asset Management LLC now owns 3,676,224 shares of the company's stock valued at $177,304,000 after purchasing an additional 34,660 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Sanofi by 6.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company's stock valued at $181,764,000 after purchasing an additional 211,641 shares in the last quarter. Finally, Raymond James Financial Inc. grew its holdings in Sanofi by 15.1% during the 1st quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company's stock valued at $179,914,000 after purchasing an additional 425,597 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "hold" rating to a "buy" rating in a report on Tuesday, September 2nd. Morgan Stanley upgraded Sanofi from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Wall Street Zen upgraded Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. JPMorgan Chase & Co. upgraded Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Finally, Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $62.67.

Sanofi Stock Performance

Shares of SNY traded up $0.30 during mid-day trading on Wednesday, hitting $47.16. The stock had a trading volume of 1,169,012 shares, compared to its average volume of 2,590,597. The company has a market cap of $115.79 billion, a PE ratio of 11.32, a PEG ratio of 1.10 and a beta of 0.51. The company's fifty day simple moving average is $48.58 and its two-hundred day simple moving average is $51.03. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a fifty-two week low of $44.73 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.Sanofi's revenue was down 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.73 EPS. On average, equities analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.